Effectiveness of angionten II receptor blocker (ARB), candesartan, in the treatment of hormone refractory prostate cancer (HRPC).

被引：0
|
作者：
Uemura, H [1 ]
Miyoshi, Y [1 ]
Ishiguro, H [1 ]
Nakaigawa, N [1 ]
Noguchi, K [1 ]
Kubota, Y [1 ]
机构：
[1] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4614
引用
收藏
页码：410S / 410S
页数：1
相关论文
共 50 条
  • [31] Phase II study of CC-4047 in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC)
    Floissac, M
    Knight, R
    Levin, A
    Glode, LM
    Crawford, ED
    Amato, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
  • [32] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    [J]. Investigational New Drugs, 2008, 26 : 75 - 79
  • [33] Gefitinib (IressaTM) combined with endocrine manipulation in patients with hormone refractory prostate cancer (HRPC).
    de Braud, FG
    Curigliano, G
    De Pas, T
    Noberasco, C
    Renne, G
    Zorzino, L
    Scardino, E
    Del Monaco, D
    De Cobelli, O
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9022S - 9022S
  • [34] The Dynamics of PSA during Hormone-Refractory Prostate Cancer (HRPC) Chemotherapy (CT)
    Sergeeva, N. S.
    Marshutina, N. V.
    Bolotina, L. V.
    Parilova, N. K.
    [J]. TUMOR BIOLOGY, 2008, 29 : 49 - 49
  • [35] A phase II trial of 13-cis retinoic acid, interferon, docetaxel, and estramustine (RITE) for the treatment of hormone refractory prostate cancer (HRPC)
    Mehta, A.
    Stein, M. N.
    Goodin, S.
    Doyle-Lindrud, S.
    Todd, M.
    Rubin, E.
    White, E.
    Jeyamohan, C.
    Metzger, D.
    DiPaola, R. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients
    Humphreys, M. R.
    Ma, C.
    Sridhar, S. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A randomized dose-finding phase II study of ifosfamide (IF) in metastatic hormone-refractory prostate cancer (HRPC).
    Hervonen, P
    Lehtinen, T
    Tammela, TLJ
    Kellokumpu-Lehtinen, P
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 76 - 76
  • [38] A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC)
    Hervonen, P
    Lehtinen, T
    Tammela, TL
    Kellokumpu-Lehtinen, P
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2002, 21 (02) : 177 - 180
  • [39] Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC)
    Hudes, GR
    Celano, P
    Torti, F
    Tabatabai, A
    Murgo, A
    Hussain, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 431S - 431S
  • [40] A phase II study of sorafenib in combination with bicalutamide in patients with chemo-naive hormone refractory prostate cancer (HRPC)
    Beardsley, E. K.
    Ellard, S. L.
    Holte, S. J.
    North, S. A.
    Winquist, E.
    Chi, K. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345